• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Charles River Labs Lowers Guidance, Acquires Two Companies

Charles River Labs Lowers Guidance, Acquires Two Companies

August 7, 2009
CenterWatch Staff

At the same timeCharles River Laboratories announced the acquisition of two companies, the preclinical contract research organization (CRO) lowered its full-year guidance for 2009.

In second-quarter financial results released earlier this week, Charles River’s net sales and income both decreased from the same period last year. Sales for the quarter fell 12.5% to $308.2 million, down from $352.1 million in the second quarter of 2008. Net income for Q2 2009 was $34.2 million, or $0.52 per diluted share, compared to net income of $49.1 million, or $0.70 per diluted share, last year.

The Wilmington, Mass.-based company reduced its full-year earnings per share estimate to be in the range of $1.78 to $1.90, down from the range $1.86 to $2.16.

Along with its second-quarter results, Charles River announced the recent acquisition of Finland-based Cerebricon, a discovery services provider, and the pending purchase of Systems Pathology Company (SPC), a pathology-based software provider.

Cerebricon was purchased for $9 million in cash and will become a part of Charles River Discovery and Imaging Services.

SPC will be acquired for an initial payment of approximately of $24 million with future payments based on certain undisclosed milestones. This deal is expected to close by the end of August.

“We have focused our efforts on identifying those assets and arrangements which we believe will position us to offer our clients novel solutions to the challenges of drug development. Each of these deals brings unique capabilities to Charles River, which we believe are a strategic advantage as we endeavor to offer value-added solutions,” Charles River chairman, president and CEO James Foster said in a statement.

Upcoming Events

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing